Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Aug 6;69(8):e0195024.
doi: 10.1128/aac.01950-24. Epub 2025 Jun 18.

Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients

Rujia Xie  1 , Halley Rogers  2 , Joseph W Chow  3 , Elena Soto  4 , Susan R Raber  5
Affiliations
Clinical Trial

Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients

Rujia Xie et al. Antimicrob Agents Chemother. .

Abstract

Aztreonam-avibactam, a fixed-ratio (3:1) β-lactam/β-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired/ventilator-associated pneumonia, and other infections due to aerobic gram-negative organisms with limited treatment options. Pharmacokinetic data from two phase 3 trials were added to previous data to develop a simultaneous aztreonam and avibactam population pharmacokinetic model. The final model was used to simulate exposures by infection type and renal function and estimate the joint probability of pharmacodynamic target attainment (PTA) for phase 3 patients (aztreonam 60% fT >MICATM-AVI of 8 mg/L and avibactam 50% fT >CT of 2.5 mg/L). Additional simulations evaluated simplified loading doses, regimens for end-stage renal disease, and ceftazidime-avibactam + aztreonam regimens. The final model included 4,914 aztreonam plasma samples (431 subjects) and 18,222 avibactam plasma samples (2,635 subjects). A two-compartment model with zero-order infusion and first-order elimination best fit the data. Time-varying creatinine clearance was a key covariate on clearance for both drugs, whereas infection type was a key covariate on clearance and volume, with the lowest exposures observed in patients with cIAI. Final aztreonam-avibactam dose regimens achieved joint PTA 89% to >99% at steady state across renal function groups. Ceftazidime-avibactam + aztreonam dose regimens proposed by the Infectious Diseases Society of America (IDSA) achieved joint PTA <85% due to insufficient avibactam exposures. Approved aztreonam-avibactam dose regimens (single loading dose and regular maintenance doses, all 3 h intravenous infusions) are optimized for joint PTA across renal function groups and infection types.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT03329092 and NCT03580044.

Keywords: aztreonam-avibactam; pharmacodynamics; population pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

E.S. and H.R. are employees of Pfizer. R.X., J.W.C., and S.R.R. are former employees of Pfizer. All authors are shareholders of Pfizer.

Similar articles

See all similar articles

References

    1. Antimicrobial Resistance Collaborators . 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629–655. doi: 10.1016/S0140-6736(21)02724-0 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention . 2019. Antibiotic resistance threats in the United States, 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re...
    1. Centers for Disease Control and Prevention . 2022. COVID-19: U.S. impact on antimicrobial resistance, special report 2022. U.S. Department of Health and Human Services,Atlanta, GA. Available from: https://stacks.cdc.gov/view/cdc/119025/cdc_119025_DS1.pdf
    1. Cornely OA, Cisneros JM, Torre-Cisneros J, Rodríguez-Hernández MJ, Tallón-Aguilar L, Calbo E, Horcajada JP, Queckenberg C, Zettelmeyer U, Arenz D, Rosso-Fernández CM, Jiménez-Jorge S, Turner G, Raber S, O’Brien S, Luckey A, COMBACTE-CARE consortium/REJUVENATE Study Group . 2020. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother 75:618–627. doi: 10.1093/jac/dkz497 - DOI - PMC - PubMed
    1. Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J, Singer G, Titov I, Gumenchuk I, Zhao Y, Jimenez-Rodriguez RM, Liang L, Chen G, Pyptiuk O, Aksoy F, Rogers H, Wible M, Arhin FF, Luckey A, Leaney JL, Pypstra R, Chow JW. 2025. Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect Dis 25:218–230. doi: 10.1016/S1473-3099(24)00499-7 - DOI - PubMed

Publication types

MeSH terms

Associated data